Vaxcyte, Inc. (PCVX) fair value analysis
Nasdaq · Updated 2026-10-19
PCVX price how computed
Valuation status
No fair-value estimate yetPCVX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for PCVX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $63.62
- Sector
- Healthcare
- 12-month range
- $40.32–$73.82
- Market cap
- $10B
- From 52-week high
- -13.8%
- Shares outstanding
- 157M
- Rank in Healthcare by quality score
- #260 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Vaxcyte, Inc. is a clinical-stage biopharmaceutical company that develops vaccines for infectious diseases. The company is headquartered in San Francisco, California.
PCVX currently ranks #260 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $10B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-7.63
- Debt / equity
- 0.04
- Shares outstanding
- 157M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 50 · neutral
- 50-day average
- $61.08
- 200-day average
- $56.23
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 1 beat, 7 missed
- Quarter by quarter
- 2026-06 ▼ miss (-34.0%)
2026-03 ▼ miss (-29.9%)
2025-12 ▼ miss (-22.4%)
2025-09 ▼ miss (-25.8%)
2025-06 ▼ miss (-5.2%)
2025-03 ▼ miss (-7.2%)
2024-12 ▼ miss (-2.6%)
2024-09 ▲ beat (+16.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 1 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $117
- Target vs last price
- +83.9%
What our data shows for PCVX
- Shares are trading in the upper third of their 12-month price range of $40.32–$73.82.
- The 14-day relative strength index sits at a neutral 50.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- PCVX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the PCVX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for PCVX show a shift in the 50/200-day trend state from mixed to uptrend this week. The healthcare sector stock's valuation verdict remains awaiting full valuation as of this reporting period.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is PCVX stock undervalued?
TickrTrends has no fair-value estimate for PCVX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is PCVX's TickrTrends verdict?
PCVX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does PCVX compare to other Healthcare stocks?
PCVX ranks #260 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is PCVX overbought or oversold?
PCVX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does PCVX report earnings next?
PCVX's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does PCVX usually beat earnings estimates?
Over its last 8 reported quarters PCVX beat the consensus estimate 1 times and missed 7 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PCVX?
Of 11 analysts covering PCVX, 10 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $117 (+83.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.